Efficiently specified ventral midbrain dopamine neurons from human pluripotent stem cells under Xeno-free conditions restore motor deficits in Parkinsonian rodents

Jonathan C. Niclis, Carlos W. Gantner, Walaa F. Alsanie, Stuart J. McDougall, Chris R Bye, Andrew G. Elefanty, Edouard G. Stanley, John M. Haynes, Colin W. Pouton, Lachlan H. Thompson, Clare L. Parish

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)

Abstract

Recent studies have shown evidence for the functional integration of human pluripotent stem cell (hPSC)-derived ventral midbrain dopamine (vmDA) neurons in animal models of Parkinson’s disease. Although these cells present a sustainable alternative to fetal mesencephalic grafts, a number of hurdles require attention prior to clinical translation. These include the persistent use of xenogeneic reagents and challenges associated with scalability and storage of differentiated cells. In this study, we describe the first fully defined feeder- and xenogeneic-free protocol for the generation of vmDA neurons from hPSCs and utilize two novel reporter knock-in lines (LMX1A-eGFP and PITX3-eGFP) for in-depth in vitro and in vivo tracking. Across multiple embryonic and induced hPSC lines, this “next generation” protocol consistently increases both the yield and proportion ofvmDAneural progenitors (OTX2/FOXA2/LMX1A) and neurons (FOXA2/TH/PITX3) that display classical vmDA metabolic and electrophysiological properties. We identify the mechanism underlying these improvements and demonstrate clinical applicability with the first report of scalability and cryopreservation of bona fide vmDA progenitors at a time amenable to transplantation. Finally, transplantation of xeno-free vmDA progenitors from LMX1A- and PITX3-eGFP reporter lines into Parkinsonian rodents demonstrates improved engraftment outcomes and restoration of motor deficits. These findings provide important and necessary advancements for the translation of hPSC-derived neurons into the clinic.

Original languageEnglish
Pages (from-to)937-948
Number of pages12
JournalStem Cells Translational Medicine
Volume6
Issue number3
DOIs
Publication statusPublished - 1 Mar 2017

Keywords

  • Dopamine neurons
  • Human pluripotent stem cells
  • LMX1A
  • Parkinson’s disease
  • PITX3
  • Ventral midbrain
  • Xenogeneic-free

Cite this

Niclis, Jonathan C. ; Gantner, Carlos W. ; Alsanie, Walaa F. ; McDougall, Stuart J. ; Bye, Chris R ; Elefanty, Andrew G. ; Stanley, Edouard G. ; Haynes, John M. ; Pouton, Colin W. ; Thompson, Lachlan H. ; Parish, Clare L. / Efficiently specified ventral midbrain dopamine neurons from human pluripotent stem cells under Xeno-free conditions restore motor deficits in Parkinsonian rodents. In: Stem Cells Translational Medicine. 2017 ; Vol. 6, No. 3. pp. 937-948.
@article{4baadd224a84460ebc87ff78f95d5ffa,
title = "Efficiently specified ventral midbrain dopamine neurons from human pluripotent stem cells under Xeno-free conditions restore motor deficits in Parkinsonian rodents",
abstract = "Recent studies have shown evidence for the functional integration of human pluripotent stem cell (hPSC)-derived ventral midbrain dopamine (vmDA) neurons in animal models of Parkinson’s disease. Although these cells present a sustainable alternative to fetal mesencephalic grafts, a number of hurdles require attention prior to clinical translation. These include the persistent use of xenogeneic reagents and challenges associated with scalability and storage of differentiated cells. In this study, we describe the first fully defined feeder- and xenogeneic-free protocol for the generation of vmDA neurons from hPSCs and utilize two novel reporter knock-in lines (LMX1A-eGFP and PITX3-eGFP) for in-depth in vitro and in vivo tracking. Across multiple embryonic and induced hPSC lines, this “next generation” protocol consistently increases both the yield and proportion ofvmDAneural progenitors (OTX2/FOXA2/LMX1A) and neurons (FOXA2/TH/PITX3) that display classical vmDA metabolic and electrophysiological properties. We identify the mechanism underlying these improvements and demonstrate clinical applicability with the first report of scalability and cryopreservation of bona fide vmDA progenitors at a time amenable to transplantation. Finally, transplantation of xeno-free vmDA progenitors from LMX1A- and PITX3-eGFP reporter lines into Parkinsonian rodents demonstrates improved engraftment outcomes and restoration of motor deficits. These findings provide important and necessary advancements for the translation of hPSC-derived neurons into the clinic.",
keywords = "Dopamine neurons, Human pluripotent stem cells, LMX1A, Parkinson’s disease, PITX3, Ventral midbrain, Xenogeneic-free",
author = "Niclis, {Jonathan C.} and Gantner, {Carlos W.} and Alsanie, {Walaa F.} and McDougall, {Stuart J.} and Bye, {Chris R} and Elefanty, {Andrew G.} and Stanley, {Edouard G.} and Haynes, {John M.} and Pouton, {Colin W.} and Thompson, {Lachlan H.} and Parish, {Clare L.}",
year = "2017",
month = "3",
day = "1",
doi = "10.5966/sctm.2016-0073",
language = "English",
volume = "6",
pages = "937--948",
journal = "Stem Cells Translational Medicine",
issn = "2157-6564",
publisher = "Alphamed Press",
number = "3",

}

Efficiently specified ventral midbrain dopamine neurons from human pluripotent stem cells under Xeno-free conditions restore motor deficits in Parkinsonian rodents. / Niclis, Jonathan C.; Gantner, Carlos W.; Alsanie, Walaa F.; McDougall, Stuart J.; Bye, Chris R; Elefanty, Andrew G.; Stanley, Edouard G.; Haynes, John M.; Pouton, Colin W.; Thompson, Lachlan H.; Parish, Clare L.

In: Stem Cells Translational Medicine, Vol. 6, No. 3, 01.03.2017, p. 937-948.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Efficiently specified ventral midbrain dopamine neurons from human pluripotent stem cells under Xeno-free conditions restore motor deficits in Parkinsonian rodents

AU - Niclis, Jonathan C.

AU - Gantner, Carlos W.

AU - Alsanie, Walaa F.

AU - McDougall, Stuart J.

AU - Bye, Chris R

AU - Elefanty, Andrew G.

AU - Stanley, Edouard G.

AU - Haynes, John M.

AU - Pouton, Colin W.

AU - Thompson, Lachlan H.

AU - Parish, Clare L.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Recent studies have shown evidence for the functional integration of human pluripotent stem cell (hPSC)-derived ventral midbrain dopamine (vmDA) neurons in animal models of Parkinson’s disease. Although these cells present a sustainable alternative to fetal mesencephalic grafts, a number of hurdles require attention prior to clinical translation. These include the persistent use of xenogeneic reagents and challenges associated with scalability and storage of differentiated cells. In this study, we describe the first fully defined feeder- and xenogeneic-free protocol for the generation of vmDA neurons from hPSCs and utilize two novel reporter knock-in lines (LMX1A-eGFP and PITX3-eGFP) for in-depth in vitro and in vivo tracking. Across multiple embryonic and induced hPSC lines, this “next generation” protocol consistently increases both the yield and proportion ofvmDAneural progenitors (OTX2/FOXA2/LMX1A) and neurons (FOXA2/TH/PITX3) that display classical vmDA metabolic and electrophysiological properties. We identify the mechanism underlying these improvements and demonstrate clinical applicability with the first report of scalability and cryopreservation of bona fide vmDA progenitors at a time amenable to transplantation. Finally, transplantation of xeno-free vmDA progenitors from LMX1A- and PITX3-eGFP reporter lines into Parkinsonian rodents demonstrates improved engraftment outcomes and restoration of motor deficits. These findings provide important and necessary advancements for the translation of hPSC-derived neurons into the clinic.

AB - Recent studies have shown evidence for the functional integration of human pluripotent stem cell (hPSC)-derived ventral midbrain dopamine (vmDA) neurons in animal models of Parkinson’s disease. Although these cells present a sustainable alternative to fetal mesencephalic grafts, a number of hurdles require attention prior to clinical translation. These include the persistent use of xenogeneic reagents and challenges associated with scalability and storage of differentiated cells. In this study, we describe the first fully defined feeder- and xenogeneic-free protocol for the generation of vmDA neurons from hPSCs and utilize two novel reporter knock-in lines (LMX1A-eGFP and PITX3-eGFP) for in-depth in vitro and in vivo tracking. Across multiple embryonic and induced hPSC lines, this “next generation” protocol consistently increases both the yield and proportion ofvmDAneural progenitors (OTX2/FOXA2/LMX1A) and neurons (FOXA2/TH/PITX3) that display classical vmDA metabolic and electrophysiological properties. We identify the mechanism underlying these improvements and demonstrate clinical applicability with the first report of scalability and cryopreservation of bona fide vmDA progenitors at a time amenable to transplantation. Finally, transplantation of xeno-free vmDA progenitors from LMX1A- and PITX3-eGFP reporter lines into Parkinsonian rodents demonstrates improved engraftment outcomes and restoration of motor deficits. These findings provide important and necessary advancements for the translation of hPSC-derived neurons into the clinic.

KW - Dopamine neurons

KW - Human pluripotent stem cells

KW - LMX1A

KW - Parkinson’s disease

KW - PITX3

KW - Ventral midbrain

KW - Xenogeneic-free

UR - http://www.scopus.com/inward/record.url?scp=85017540735&partnerID=8YFLogxK

U2 - 10.5966/sctm.2016-0073

DO - 10.5966/sctm.2016-0073

M3 - Article

VL - 6

SP - 937

EP - 948

JO - Stem Cells Translational Medicine

JF - Stem Cells Translational Medicine

SN - 2157-6564

IS - 3

ER -